Literature DB >> 15095474

Properties of SEPT9 isoforms and the requirement for GTP binding.

Claire Robertson1, Stewart W Church, Hans A Nagar, John Price, Peter A Hall, S E Hilary Russell.   

Abstract

Members of the evolutionarily conserved septin family of genes are emerging as key components of several cellular processes including membrane trafficking, cytokinesis, and cell-cycle control events. SEPT9 has been shown to have a complex genomic architecture, such that up to 15 different isoforms are possible by the shuffling of five alternate amino termini and three alternate carboxy termini. Genomic and transcriptional alterations of SEPT9 have been associated with neoplasia. The present study has used a Sept9-specific antibody to determine the pattern of isoform expression in a range of tumour cell lines. Western blot analysis indicated considerable variation in the relative amounts and isoform content of Sept9. Immunofluorescence studies showed a range of patterns of cytoplasmic localization ranging from mainly particulate to mainly filamentous. Expression constructs were also generated for each amino terminal isoform to investigate the patterns of localization of individual isoforms and the effects on cells of ectopic expression. The present study shows that the epsilon isoform appears filamentous in this overexpression system while the remaining isoforms are particulate and cytoplasmic. Transient transfection of individual constructs into tumour cell lines results in cell-cycle perturbation with a G2/M arrest and dramatic growth suppression, which was greatest in cell lines with the lowest amounts of endogenous Sept9. Similar phenotypic observations were made with GTP-binding mutants of all five N-terminal variants of Sept9. However, dramatic differences were observed in the kinetics of accumulation of wild-type versus mutant septin protein in transfected cells. In conclusion, the present study shows that the expression patterns of Sept9 protein are very varied in a panel of tumour cell lines and the functional studies are consistent with a model of septin function as a component of a molecular scaffold that contributes to diverse cellular functions. Alterations in the levels of Sept9 protein by overexpression of individual isoforms can clearly perturb cellular behaviour and may thus provide a mechanistic explanation for observations of deranged septin expression in neoplasia. Copyright 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15095474     DOI: 10.1002/path.1551

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  15 in total

1.  Expression of the SEPT9_i4 isoform confers resistance to microtubule-interacting drugs.

Authors:  Alex D Chacko; Simon S McDade; Severine Chanduloy; Stewart W Church; Richard Kennedy; John Price; Peter A Hall; S E Hilary Russell
Journal:  Cell Oncol (Dordr)       Date:  2012-01-26       Impact factor: 6.730

Review 2.  Understanding cytokinesis failure.

Authors:  Guillaume Normand; Randall W King
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

Review 3.  Some assembly required: yeast septins provide the instruction manual.

Authors:  Matthias Versele; Jeremy Thorner
Journal:  Trends Cell Biol       Date:  2005-08       Impact factor: 20.808

Review 4.  The evolution, complex structures and function of septin proteins.

Authors:  Lihuan Cao; Wenbo Yu; Yanhua Wu; Long Yu
Journal:  Cell Mol Life Sci       Date:  2009-07-14       Impact factor: 9.261

Review 5.  Clinical and pathophysiological concepts of neuralgic amyotrophy.

Authors:  Nens van Alfen
Journal:  Nat Rev Neurol       Date:  2011-05-10       Impact factor: 42.937

6.  Disruption of Sept6, a fusion partner gene of MLL, does not affect ontogeny, leukemogenesis induced by MLL-SEPT6, or phenotype induced by the loss of Sept4.

Authors:  Ryoichi Ono; Masafumi Ihara; Hideaki Nakajima; Katsutoshi Ozaki; Yuki Kataoka-Fujiwara; Tomohiko Taki; Koh-Ichi Nagata; Masaki Inagaki; Nobuaki Yoshida; Toshio Kitamura; Yasuhide Hayashi; Makoto Kinoshita; Tetsuya Nosaka
Journal:  Mol Cell Biol       Date:  2005-12       Impact factor: 4.272

7.  Alternative splicing of sept9a and sept9b in zebrafish produces multiple mRNA transcripts expressed throughout development.

Authors:  Megan L Landsverk; Douglas C Weiser; Mark C Hannibal; David Kimelman
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

8.  Duplication within the SEPT9 gene associated with a founder effect in North American families with hereditary neuralgic amyotrophy.

Authors:  Megan L Landsverk; Elizabeth K Ruzzo; Heather C Mefford; Karen Buysse; Jillian G Buchan; Evan E Eichler; Elizabeth M Petty; Esther A Peterson; Dana M Knutzen; Karen Barnett; Martin R Farlow; Judy Caress; Gareth J Parry; Dianna Quan; Kathy L Gardner; Ming Hong; Zachary Simmons; Thomas D Bird; Phillip F Chance; Mark C Hannibal
Journal:  Hum Mol Genet       Date:  2009-01-12       Impact factor: 6.150

9.  Septin 9 isoform expression, localization and epigenetic changes during human and mouse breast cancer progression.

Authors:  Diana Connolly; Zhixia Yang; Maria Castaldi; Nichelle Simmons; Maja H Oktay; Salvatore Coniglio; Melissa J Fazzari; Pascal Verdier-Pinard; Cristina Montagna
Journal:  Breast Cancer Res       Date:  2011-08-10       Impact factor: 6.466

10.  Proteomic profile of pre - B2 lymphoblasts from children with acute lymphoblastic leukemia (ALL) in relation with the translocation (12; 21).

Authors:  Odile Costa; Pascale Schneider; Laurent Coquet; Philippe Chan; Dominique Penther; Elisabeth Legrand; Thierry Jouenne; Marc Vasse; Jean-Pierre Vannier
Journal:  Clin Proteomics       Date:  2014-08-01       Impact factor: 3.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.